Hans Bishop is the Chairman of Sana Biotechnology and the Chief Executive Officer of GRAIL.

Hans founded Juno Therapeutics in 2013 and served as its President and Chief Executive Officer until the company’s acquisition by Celgene. Prior to Juno, he served as an Executive in Residence at Warburg Pincus. Earlier in his career, Hans was the Executive Vice President and Chief Operating Officer for Dendreon. He also previously served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. In addition to serving as the Chair of Sana’s Board of Directors, he serves as a Director of Celgene, Agilent Technologies, and Lyell Immunopharma.

Hans holds a BA in chemistry from Brunel University in London.